The suppression of human immunodeficiency virus (HIV) replication and elevation in CD4 cells observed with protease inhibitor combination regimens known as HAART (highly active antiretroviral therapy) may allow AIDS patients to undergo an immune recovery that allows them to suppress the progression of cytomegalovirus (CMV) retinitis. Eleven AIDS patients receiving HAART with healed CMV retinitis in whom CMV-specific maintenance therapy was discontinued were studied. Median CD4 cell counts were 42 before the initiation of HAART and 183 at discontinuation of anti-CMV therapy. While a median 1.1 log 10 drop in plasma HIV-1 RNA was obtained between starting HAART and withdrawal of maintenance therapy for CMV, only 3 of 11 patients maintained plasma HIV RNA below the limits of detection. Reactivation of CMV retinitis after withdrawal of anti-CMV therapy did not occur in any of the patients observed for a median of 156 days (range, 92 -558).
Protease inhibitor -containing antiretroviral combination to the use of HAART [7] . However, protection from new CMV disease may depend in part on the duration of HAART, because therapy can produce substantial drops in plasma human immunodeficiency virus (HIV) RNA and elevations in CD4 cells for CMV retinitis was diagnosed in 10 patients who received HAART for õ2 months and who had CD4 T lymphocyte up to 6 months, even in patients with advanced disease and CD4 cell counts õ50/mm 3 [1, 2]. An associated significant counts ú100/mm 3 [8 -10] . For persons with established disease, the natural history of decrease in the risk of opportunistic infection and an improved survival in response to these regimens has also been docu-CMV retinitis before the HAART era is well documented. Progression of retinitis consistently develops within 8 weeks in mented [3] .
Once destruction of CD4 T lymphocytes has occurred, restopatients who do not continue to receive anti-CMV maintenance therapy [11 -14] . Recently, 4 patients with previously active ration of a functional repertoire by potent antiretroviral therapy may be incomplete [4] . Expansion of antigen-specific memory CMV retinitis, who experienced rises in CD4 cell counts in response to HAART, were reported to have unusually extended T cells may occur only in the presence of continuous antigenic stimulation [4] . Recent studies of the effect of highly active intervals free of CMV retinitis progression without specific anti-CMV maintenance therapy [15] . Because of the ability to antiretroviral therapy (HAART) in HIV-infected persons have shown both polyclonal expansion of the memory T cell reperdetect even subtle reactivations before vision loss occurs, CMV retinitis provides an excellent opportunity to test the hypothesis toire and improvement of in vitro CD4 T lymphocyte function [4 -6] . However, it remains unclear whether reconstitution of that in patients with HAART-induced elevations in CD4 cell counts and stable healed CMV retinitis, protection against naive T cells after deletion secondary to HIV infection is possible.
CMV is restored. In this report, we characterize the ophthalmologic and virologic outcomes of 11 patients who discontinued A dramatic decrease in the incidence of cytomegalovirus (CMV) retinitis in recent years has been reported and attributed anti-CMV maintenance therapy for up to 18 months. CMV therapy. Subsequently, all patients received HAART and or cidofovir [11, [17] [18] [19] . To improve their lifestyle and reduce drug-related morbidity, they opted to discontinue anti-CMV therexperienced elevations in CD4 cell counts.
In 4 of 8 patients, anti-CMV therapy was discontinued. Three apy and informed the physicians and ophthalmologists of their decision to ensure closer follow-up. patients were receiving as-needed intravitreal cidofovir while participating in a study of intraocular cidofovir, and reactivation of UCSD patients with CMV retinitis, who were not receiving systemic anti-CMV therapy, who had CD4 cell counts below 45/ CMV retinitis never occurred [16] . In addition to local cidofovir therapy, 2 of these patients did not adhere to the prescribed oral mm 3 , and who were participating in a study from 21 November 1995 to 26 November 1996 to determine time to progression after ganciclovir for systemic coverage. The fourth patient discontinued oral ganciclovir that he was receiving following a course of intravea single injection of intraocular cidofovir, served as controls. In addition, the UCSD AIDS Ocular Research Unit database was nous ganciclovir.
The remaining 4 consecutive UCSD patients had no CMV retinisearched from 1 December 1995 to 2 May 1997 to determine the number of patients with CMV retinitis who had received tis progression for more than twice the expected median time to progression while receiving either oral or intravenous ganciclovir HAART. border advancement.
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Data analysis. Data were analyzed with JMP statistical softSaquinavir, 3TC, AZT 9 ware (SAS Institute, Cary, NC). Continuous variables were com- sponded to HAART and controls was compared by the KaplanMeier survival log-rank method (JMP software; SAS). ; plasma HIV-1 RNA is log 10 copies/mL. CMVR, CMV retinitis; OD, intravitreal right eye; OS, intravitreal left eye; A, active; H, healed; N, none. CMVTx, anti-CMV treatment; stop CMVTx, cessation of anti-CMV maintenance therapy. GCV, ganciclovir; FOS, foscarnet; CDV, cidofovir; IDV, indinavir; RIT, ritonavir; SAQ, saquinavir; 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; iv, intravenous.
Results
in plasma HIV RNA since starting HAART and maintenance withdrawal), this effect was not sustained (table 2) . In fact, All 11 CMV patients who discontinued anti-CMV therapy at withdrawal of anti-CMV maintenance therapy, the median remained healed for the entire observation period (mean { SE, plasma HIV RNA level was 3.95 log 10 copies/mL and was 210 { 42 days; median, 156; range, 92 -558) (figure 1).
below the limits of detection of the assay (õ2.60 log 10 copies/ Demographic characteristics and clinical and laboratory mL) for only 3 of 11 patients (mean { SE, 4.91 { 4.65 log 10 findings at the time of anti-CMV maintenance therapy disconcopies/mL; range, 3.16 -5.71). At that time, subjects had retinuation in 11 AIDS patients are shown in table 1. The majority ceived HAART for a median of 271 days (range, 97 -587), of subjects were middle-aged Caucasian men, who had been and 5 of 11 patients had been switched to another protease treated for zone 2 -3 CMV retinitis for an average of 1.5 years inhibitor because of intolerance to the medication or of increas-(range, 0.7 -3.1). Bilateral disease was present but inactive in ing plasma HIV RNA levels. 6 patients, and 82% of patients were receiving oral ganciclovir At the most recent visit, median CD4 cell counts remained at the time of discontinuation of anti-CMV maintenance. The elevated at 223/mm 3 (mean { SE, 259 { 47; range, 44 -507), patients had experienced an average of 1.3 reactivations of and plasma HIV RNA was not detected in the 3 previously CMV retinitis before withdrawal of specific therapy.
suppressed patients. In the remaining patients with incomplete At CMV maintenance withdrawal, patient 3 was receiving antiretroviral effect, median plasma HIV RNA was 3.64 log 10 only lamivudine and zidovudine and never needed a second copies/mL (mean { SE, 3.85 { 0.34; range, 2.61 -5.63). injection of intraocular cidofovir. Later, ritonavir was added When pre-HAART values were compared with those at the to his antiretroviral treatment (table 2) .
time of discontinuation of CMV maintenance therapy, CD4 Absolute CD4 cell counts and plasma HIV RNA levels at cell counts were significantly higher (P Å .004), while the CMV diagnosis and during the period of observation are shown median 1.1 log 10 drop in plasma HIV RNA levels was not in table 2. Median CD4 cell counts were 42/mm 3 (range, 0 -significant. 119) at diagnosis of CMV retinitis compared with 183/mm 3 Control group. The UCSD control group consisted of 27 (range, 63 -404) when CMV maintenance was discontinued.
patients with CD4 cell counts õ45/mm 3 participating in a Two persons started HAART 19 and 34 days before the diagnotrial designed to determine the time to progression after a sis of CMV retinitis was made and already had experienced single injection of intravitreal cidofovir. Though 10 (37%) of elevations in CD4 cell counts (from 30 to 119 and from 30 to 27 were receiving HAART, this treatment had not induced 111/mm 3 , respectively).
increases in CD4 cell counts. In this group, the median time Plasma HIV RNA levels at diagnosis of CMV retinitis, availto progression was 56 days [16] . The difference in time to able for 4 of 11 patients, were 5.62, 4.64, 3.76, and 4.60 log 10 progression between the 2 groups was highly significant by copies/mL. While HAART regimens were successful in lowering plasma HIV RNA in most patients (median, 1.1 log 10 drop log-rank test (P õ .001). Use of HAART among patients with CMV retinitis. RNA levels were 26,000 (4.40 log 10 ) copies/mL (range, 8000 -419,000), at anti-CMV therapy withdrawal they had decreased Ninety-four percent of patients with CMV retinitis (102/108) were receiving HAART during the 18-month observation peby 1.1 log 10 (median, 8900 [3.95 log 10 ] copies/mL; range, õ400 -508,000). As has been described previously and was riod (1 December 1995 to 2 May 1997). Of all CMV patients receiving HAART, only 7.8% (8/102) remained healed withobserved in our population, a virologic response preceded the CD4 T cell rise. Thus, the ability to control reactivation of out therapy for ú80 days. Twelve (23%) of 52 CMV retinitis patients had both CD4 cell counts above 60/mm 3 and inactive CMV retinitis without specific anti-CMV treatment suggests that a T cell -mediated response confers protection against CMV retinitis.
CMV and that partial immune recovery is possible, even at late stages of AIDS, in spite of high levels of HIV replication, Discussion as evidenced by persistently measurable plasma HIV-1 RNA levels in 8 of 11 patients. We report on the outcome of 11 AIDS patients with healed CMV retinitis and significant elevations in absolute CD4 cells Before the availability of HAART, the risk of CMV retinitis was highest as CD4 cell counts dropped below 50/mm 3 [23] . following HAART who discontinued specific anti-CMV maintenance therapy. It has previously been shown that in iatrogeniThis threshold may be unchanged for new disease, since the incidence of CMV has decreased in patients responding to cally immunosuppressed transplant patients, immune recovery can be accomplished by decreasing the dose of immunosuppotent antiretroviral combinations. For established CMV retinitis, we have observed at both institutions unusually long periods pressive medications [22] . The lack of reactivation without specific anti-CMV maintenance in all 11 patients at two sepaof retinitis inactivity, even in patients treated with oral ganciclovir and who experienced more modest rises in CD4 cell rate institutions, during a median observation of 156 days, supports the hypothesis that AIDS patients responding to counts (between 45 and 60/mm 3 ), suggesting that a modification of the history of treated disease may have occurred. Addi-HAART may regain the ability to suppress CMV replication.
Four of the 11 patients had received intravitreal cidofovir tionally, the risks for progression in patients in whom HAART subsequently fails and who have decreasing CD4 cell counts during their course of anti-CMV therapy. These injections were given 8 months, 6 months, 4 months, and 5 weeks before may also be different. Studies of systemic CMV infections in AIDS patients have discontinuation of all anti-CMV therapy. To assess the possible impact of this long-term therapy on the study cohort, demonstrated that the retina is usually the most common and earliest site of clinically significant infection with CMV [24] . they were compared with a control group who all received intravitreal cidofovir at day 1 of their period of healed retinitis.
Masked wide-angle fundus photographs are an essential tool for the unbiased documentation of progression of CMV retinitis The study cohort showed a much greater period of healing (P õ .001, log-rank). It should be noted that the duration of and can discriminate accurately an advancement of border activity õ750 mm before any significant vision loss occurs [14, action of intravitreal cidofovir is 5 -10 weeks and could not account for the prolonged period of lack of progression in the 20]. Treatment of CMV is associated with drug toxicities, morbidity, complicated scheduling, and significant costs [11, 25 -study patients [18] .
The lack of reactivation or progression was also associated 27]. Treatment alone could negatively influence functional health status and even interfere with adherence to antiretroviral with a stability of visual acuity. No patient lost central vision due to progression of a CMV retinitis border. In addition, regimens. Thus, CMV retinitis seems the ideal setting for the exploration of new management strategies, such as frequent although visual field testing was not done, it has been shown that visual field loss in CMV retinitis corresponds to the CMV optimal monitoring versus drug intervention. A multicenter prospective trial is being designed to further characterize lesion and that it is very unlikely that visual field loss could have occurred [21] .
HAART-related immune recovery in patients with CMV retinitis. While reactivation of CMV retinitis has been observed in some patients with elevated CD4 cell counts, sustained CMV inactivity was noted at our institutions, even before anti-CMV
